Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC)
暂无分享,去创建一个
J. Hainsworth | T. Ciuleanu | V. Tzekova | N. Sanders | P. Stella | G. Pover | C. Cebotaru | H. Ganchev | D. Damjanov | Vladimir Kanarev